0001140361-24-046726 | 10-Q | XBRL Viewer | Galectin Therapeutics INC

Convertible Line of Credit - Related Party	9 Months Ended
Convertible Line of Credit - Related Party	Sep. 30, 2024
Line of Credit [Member]
Debt Instrument [Line Items]
Convertible Line of Credit - Related Party	9. Convertible Line of Credit – Related Party On July 25, 2022, the Company and Richard E. Uihlein (the “Lender”) entered into a Line of Credit Letter Agreement (the “Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $60.0 million (the “Line of Credit”) to finance the Company’s working capital needs. The Company may draw upon the Line of Credit through July 31, 2024. Each advance made pursuant to the Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a “Promissory Note,” and collectively, the “Promissory Notes”), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before January 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid. At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company’s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share. In connection with the Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 1,700,000 shares of the Company’s common stock, par value $0.001 per share (collectively, the “Warrants”). Upon execution of the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 500,000 shares of Company’s Common Stock at an exercise price of $5.00 per share, which Warrant is exercisable upon issuance. Further, pursuant to the Credit Agreement, the Company shall issue to the Lender additional Warrants to purchase up to the remaining 1,200,000 shares of the Company’s common stock, ratably, upon borrowings under the Credit Agreement, with exercise prices equal to 150% of the closing price of the Company’s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. The Warrants expire on July 31, 2029. The fair value of the 500,000 warrants vested at closing on July 25, 2022 was $738,000 at the date of issuance based on the following assumptions: an expected life of 7 years, volatility of 92%, risk free interest rate of 3.19% and zero dividends. The fair value of the vested warrants was recorded in other assets (non-current) as a deferred financing cost and will be amortized on a straight-line basis from July 25, 2022 through January 31, 2026. Amortization for the three months ended September 30, 2024 and 2023 of $52,000 and $52,000, respectively, was recorded as interest expense. Amortization for the nine months ended September 30, 2024 and 2023 of $156,000 and $157,000, respectively, was recorded as interest expense. On December 19, 2022, the Company executed a $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 6.46% (Applicable Federal Rate for short term loans on date of draw of 4.46% plus 2%). The effective interest rate is approximately 7.1%. Accrued interest on this draw was $1,217,000 and $517,000 at September 30, 2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company’s Common Stock at an exercise price of $3.00 per share, which Warrant is exercisable upon issuance. The fair value of the 200,000 warrants vested at closing on December 19, 2022 was $160,780 at the date of issuance based on the following assumptions: an expected life of 7 years, volatility of 91%, risk free interest rate of 4.06% and zero dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not materially different than the effective interest method, from December 19, 2022 through January 31, 2026. Amortization for the nine months ended September 30, 2024 and 2023 of $39,000 in each period and was recorded as interest expense. The fair value of warrants that vest in the future based on borrowings will be computed when those borrowings occur and amortized over the remaining period through January 31, 2026. On March 31, 2023, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 6.41% (Applicable Federal Rate for short term loans on date of draw of 4.41% plus 2%). The effective interest rate is approximately 7.1%. Accrued interest on this draw was $1,006,000 and $325,000 at September 30, 2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company’s Common Stock at an exercise price of $3.26 per share, which Warrant is exercisable upon issuance. The fair value of the 200,000 warrants vested at closing on March 31, 2023 was $296,680 at the date of issuance based on the following assumptions: an expected life of 6.33 years, volatility of 88%, risk free interest rate of 3.94% and zero dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal to be amortized on a straight-line basis, which is not materially different than the effective interest method, from March 31, 2023 through January 31, 2026. Amortization for the nine months ended September 30, 2024 and 2023 of $78,000 and $52,000, respectively, was recorded as interest expense. On June 30, 2023, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 6.34% (Applicable Federal Rate for short term loans on date of draw of 4.34% plus 2%). The effective interest rate is approximately 7.1%. Accrued interest on this draw was $822,000 and $159,000 at September 30, 2024 and 2023, respectively. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company’s Common Stock at an exercise price of $3.00 per share, which Warrant is exercisable upon issuance. The fair value of the 200,000 warrants vested at closing on June 30, 2023 was $179,920 at the date of issuance based on the following assumptions: an expected life of 6.08 years, volatility of 85%, risk free interest rate of 3.59% and zero dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method, from June 30, 2023 through January 31, 2026. Amortization for the nine months ended September 30, 2024 and 2023 of $52,000 and $18,000, respectively, was recorded as interest expense. On December 29, 2023, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 7.13% (Applicable Federal Rate for short term loans on date of draw of 5.13% plus 2%). The effective interest rate is approximately 7.5%. Accrued interest on this draw was $548,000 September 30, 2024. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company’s Common Stock at an exercise price of $3.00 per share, which Warrant is exercisable upon issuance. The fair value of the 200,000 warrants vested at closing on December 31, 2023 was $193,745 at the date of issuance based on the following assumptions: an expected life of 5.7 years, volatility of 79%, risk free interest rate of 4.49% and zero dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method, from December 29, 2023 through January 31, 2026. Amortization for the nine months ended September 30, 2024 of $70,000 was recorded as interest expense. On March 29, 2024, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 6.62% (Applicable Federal Rate for short term loans on date of draw of 4.62% plus 2%). The effective interest rate is approximately 7.1%. Accrued interest on this draw was $166,000 at September 30, 2024. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company’s Common Stock at an exercise price of $3.59 per share, which Warrant is exercisable upon issuance. The fair value of the 200,000 warrants vested at closing on March 29, 2024, was $277,389 at the date of issuance based on the following assumptions: an expected life of 5.33 years, volatility of 75%, risk free interest rate of 4.19% and zero dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method, from March 29, 2024 through January 31, 2026. Amortization for the nine months ended September 30, 2024 of $76,000 was recorded as interest expense. On June 28, 2024, the Company executed an additional $10 million Promissory Note under the Line of Credit. The interest rate on this draw is 7.01% (Applicable Federal Rate for short term loans on date of draw of 5.01% plus 2%). The effective interest rate is approximately 7.4%. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company’s Common Stock at an exercise price of $3.39 per share, which Warrant is exercisable upon issuance. The fair value of the 200,000 warrants vested at closing on June 28, 2024, was $260,000 at the date of issuance based on the following assumptions: an expected life of 5.03 years, volatility of 77%, risk free interest rate of 4.29% and zero dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method, from June 28, 2024 through January 31, 2026. Amortization for the nine months ended September 30, 2024 of $41,000 was recorded as interest expense.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

Common Stock Warrants (Tables)

9 Months Ended

Sep. 30, 2024

Common Stock Warrants [Abstract]

Common Stock Warrant Activity

The following table summarizes the common stock warrant activity from December 31, 2023 through September 30, 2024:

	Shares			Weighted Average Exercise Price
Outstanding, December 31, 2023		9,256,493		$	4.22
Granted		600,000			3.70
Exercised		(125,093	)		3.00
Forfeited/cancelled		(108,455	)		4.49
Outstanding, September 30, 2024		9,622,945		$	4.20

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($) $ in Thousands	Preferred Stock [Member] Series A 12% Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Deficit [Member]	Total
Beginning balance at Dec. 31, 2022					$ 1,723
Beginning balance (in shares) at Dec. 31, 2022					176
Ending balance at Sep. 30, 2023					$ 1,723
Ending balance (in shares) at Sep. 30, 2023					176
Beginning balance at Dec. 31, 2022	$ 510	$ 59	$ 275,081	$ (309,567)	$ (33,917)
Beginning balance (in shares) at Dec. 31, 2022	1,260,000	59,426,005
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series A 12% convertible preferred stock dividend			50	(12)	38
Series A 12% convertible preferred stock dividend (in shares)		25,200
Series C super dividend redeemable convertible preferred stock dividend			69	(45)	24
Series C super dividend redeemable convertible preferred stock dividend (in shares)		35,200
Issuance of common stock from exercise of warrants		$ 2	10,031		10,033
Issuance of common stock from exercise of warrants (in shares)		2,236,204
Common stock purchase warrants issued in connection with related party line of credit			477		477
Warrant modification			3,619	(3,619)
Stock-based compensation expense			1,818		1,818
Stock-based compensation expense (in shares)		126,048
Net loss				(31,069)	(31,069)
Ending balance at Sep. 30, 2023	$ 510	$ 61	291,145	(344,312)	(52,596)
Ending balance (in shares) at Sep. 30, 2023	1,260,000	61,848,657
Ending balance at Sep. 30, 2023					$ 1,723
Ending balance (in shares) at Sep. 30, 2023					176
Beginning balance at Jun. 30, 2023	$ 510	$ 59	276,852	(330,271)	$ (52,850)
Beginning balance (in shares) at Jun. 30, 2023	1,260,000	59,582,253
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series A 12% convertible preferred stock dividend			24	14	39
Series A 12% convertible preferred stock dividend (in shares)		12,600
Series C super dividend redeemable convertible preferred stock dividend			33	(8)	25
Series C super dividend redeemable convertible preferred stock dividend (in shares)		17,600
Issuance of common stock from exercise of warrants		$ 2	10,031		10,033
Issuance of common stock from exercise of warrants (in shares)		2,236,204
Warrant modification			3,619	(3,619)
Stock-based compensation expense			586		516
Net loss				(10,428)	(10,428)
Ending balance at Sep. 30, 2023	$ 510	$ 61	291,145	(344,312)	(52,596)
Ending balance (in shares) at Sep. 30, 2023	1,260,000	61,848,657
Beginning balance at Dec. 31, 2023					$ 1,723
Beginning balance (in shares) at Dec. 31, 2023					176
Ending balance at Sep. 30, 2024					$ 1,723
Ending balance (in shares) at Sep. 30, 2024					176
Beginning balance at Dec. 31, 2023	$ 500	$ 61	291,847	(354,372)	$ (61,964)
Beginning balance (in shares) at Dec. 31, 2023	1,235,000	61,852,914
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series A 12% convertible preferred stock dividend			64	(27)	37
Series A 12% convertible preferred stock dividend (in shares)		24,700
Series C super dividend redeemable convertible preferred stock dividend			89	(63)	$ 26
Series C super dividend redeemable convertible preferred stock dividend (in shares)		35,200
Exercise of common stock options (in shares)		19,620			49,583
Issuance of common stock from exercise of warrants		$ 1	375		$ 376
Issuance of common stock from exercise of warrants (in shares)		125,093
Common stock purchase warrants issued in connection with related party line of credit			845		845
Stock-based compensation expense			1,556		1,556
Stock-based compensation expense (in shares)		250,548
Net loss				(35,080)	(35,080)
Ending balance at Sep. 30, 2024	$ 500	$ 62	294,776	(389,542)	(94,204)
Ending balance (in shares) at Sep. 30, 2024	1,235,000	62,308,075
Ending balance at Sep. 30, 2024					$ 1,723
Ending balance (in shares) at Sep. 30, 2024					176
Beginning balance at Jun. 30, 2024	$ 500	$ 62	293,872	(378,304)	$ (83,870)
Beginning balance (in shares) at Jun. 30, 2024	1,235,000	62,278,125
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Series A 12% convertible preferred stock dividend			34	3	37
Series A 12% convertible preferred stock dividend (in shares)		12,350
Series C super dividend redeemable convertible preferred stock dividend			47	(21)	26
Series C super dividend redeemable convertible preferred stock dividend (in shares)		17,600
Common stock purchase warrants issued in connection with related party line of credit			308		308
Stock-based compensation expense			515		515
Net loss				(11,220)	(11,220)
Ending balance at Sep. 30, 2024	$ 500	$ 62	$ 294,776	$ (389,542)	$ (94,204)
Ending balance (in shares) at Sep. 30, 2024	1,235,000	62,308,075

Accrued Expenses and Other (Tables)

9 Months Ended

Sep. 30, 2024

Accrued Expenses and Other [Abstract]

Accrued Expenses

Accrued expenses consist of the following:

	September 30, 2024		December 31, 2023
	(in thousands)
Legal and accounting fees	$	96	$	40
Accrued compensation		1,059		1,129
Lease liability		32		46
Accrued research and development costs and other		10,399		7,967
Total	$	11,586	$	9,182

Stock-Based Compensation, Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Stock Option Activity [Roll Forward]
Outstanding at beginning of period (in shares) \| shares	6,333,841
Granted (in shares) \| shares	1,373,000
Exercised (in shares) \| shares	(49,583)
Forfeited/cancelled (in shares) \| shares	(348,750)
Outstanding at end of period (in shares) \| shares	7,308,508
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 2.66
Granted (in dollars per share) \| $ / shares	1.86
Exercised (in dollars per share) \| $ / shares	(1.22)
Forfeited/cancelled (in dollars per share) \| $ / shares	(6.35)
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 2.35
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]
Unrecognized compensation cost \| $	$ 1,154,000
Unvested options (in shares) \| shares	2,475,171
Unrecognized compensation cost, recognition period	1 year
Weighted-average grant-date fair value of options granted (in dollars per share) \| $ / shares	$ 1.23

Leases

9 Months Ended

Sep. 30, 2024

Leases [Abstract]

Leases

12. Leases

The Company has one operating lease for its office space which was amended effective March 1, 2022 for a term of 38 months with no residual value guarantees or material restrictive covenants. The amended lease provided for free rent for the first six and a half months of the lease and continues the security deposit of $6,000. In addition to base rental payments included in the contractual obligations table above, the Company is responsible for our pro-rata share of the operating expenses for the building. Our lease cost for the nine-month periods ended September 30, 2024 and 2023 was approximately $39,000 for each period and is included in general and administrative expenses. As of September 30, 2024, the right to use lease asset consisted of $26,000 and is included in other assets. Also, at September 30, 2024, current lease liability of $32,000 is included in accrued expenses.

Maturity of operating lease as of September 30, 2024 in thousands:

2024		13
2025		20
Total		33
Less imputed interest		1
Present value of lease liability	$	32

The discount rate used in calculating the present value of the lease payments was 11%.

Supplemental Convertible Lines of Credit - Related Party (Details) - USD ($)				6 Months Ended	9 Months Ended
	Nov. 14, 2024	Mar. 29, 2024	Jul. 25, 2022	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Jun. 28, 2024	Dec. 31, 2023	Dec. 29, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 19, 2022
Convertible Line of Credit - Related Party [Abstract]
Common stock, par value (in dollars per share)				$ 0.001	$ 0.001			$ 0.001
Proceeds from lines of credit					$ 30,000,000	$ 20,000,000
Expected life					5 years 4 months 24 days	5 years 6 months
Expected volatility					75.00%	86.00%
Risk free interest rate					3.88%	3.84%
Expected dividend					0.00%	0.00%
Warrant [Member]
Convertible Line of Credit - Related Party [Abstract]
Warrants issuance value			$ 738,000
Expected life				4 years 9 months 29 days	7 years
Expected volatility				78.00%	92.00%
Risk free interest rate				3.58%	3.19%
Expected dividend				0.00%	0.00%
Richard E. Uihlein [Member]
Convertible Line of Credit - Related Party [Abstract]
Common stock, par value (in dollars per share)			$ 0.001
Percentage of warrants equal to the closing price of common stock			150.00%
Warrants expiry date				Jul. 31, 2029	Jul. 31, 2029
Richard E. Uihlein [Member] \| Warrant [Member]
Convertible Line of Credit - Related Party [Abstract]
Exercise price of warrant (in dollars per share)			$ 5
Richard E. Uihlein [Member] \| Supplemental Line of Credit [Member]
Convertible Line of Credit - Related Party [Abstract]
Line of credit		$ 10,000,000
Additional short term borrowing interest rate		2.00%		2.00%
Promissory Note, maturity date					Jan. 31, 2026
Percentage of warrants equal to the closing price of common stock				150.00%	150.00%
Share price (in dollars per share)				$ 3	$ 3
Warrants expiry date				Jul. 31, 2029	Jul. 31, 2029
Proceeds from lines of credit				$ 10,000,000
Interest rate on short term loans				6.13%
Short term borrowing interest rate				5.01%	5.01%
Short term borrowing effective interest rate				6.40%	6.40%
Exercise price of warrant (in dollars per share)				$ 4.13	$ 4.13
Warrants issuance value				$ 307,780
Richard E. Uihlein [Member] \| Supplemental Line of Credit [Member] \| Minimum [Member]
Convertible Line of Credit - Related Party [Abstract]
Share price (in dollars per share)				$ 3	3
Richard E. Uihlein [Member] \| Supplemental Line of Credit [Member] \| Maximum [Member]
Convertible Line of Credit - Related Party [Abstract]
Share price (in dollars per share)				10	10
Richard E. Uihlein [Member] \| Additional Supplemental Line of Credit [Member] \| Subsequent Event [Member]
Convertible Line of Credit - Related Party [Abstract]
Line of credit	$ 6,000,000
Additional short term borrowing interest rate	2.00%
Promissory Note, maturity date	Mar. 31, 2026
Warrants to purchase common stock (in shares)	120,000
Common stock, par value (in dollars per share)	$ 0.001
Percentage of warrants equal to the closing price of common stock	150.00%
Share price (in dollars per share)	$ 3
Warrants expiry date	Jul. 31, 2029
Richard E. Uihlein [Member] \| Additional Supplemental Line of Credit [Member] \| Subsequent Event [Member] \| Minimum [Member]
Convertible Line of Credit - Related Party [Abstract]
Share price (in dollars per share)	$ 3
Richard E. Uihlein [Member] \| Additional Supplemental Line of Credit [Member] \| Subsequent Event [Member] \| Maximum [Member]
Convertible Line of Credit - Related Party [Abstract]
Share price (in dollars per share)	$ 10
Common Stock [Member] \| Richard E. Uihlein [Member]
Convertible Line of Credit - Related Party [Abstract]
Warrants to purchase common stock (in shares)			1,700,000
Common stock, par value (in dollars per share)				$ 0.001	$ 0.001
Common Stock [Member] \| Richard E. Uihlein [Member] \| Maximum [Member]
Convertible Line of Credit - Related Party [Abstract]
Warrants to purchase common stock (in shares)		200,000	500,000	200,000	200,000		200,000		200,000	200,000	200,000	200,000

Common Stock	9 Months Ended
Common Stock	Sep. 30, 2024
Common Stock [Abstract]
Common Stock	8. Common Stock 2020 At Market Issuance of Common Stock On May 11, 2020, the Company entered into an At Market Issuance Sales Agreement (the “2020 At Market Agreement”) with a sales agent under which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $40.0 million from time to time through the sales agent. Sales of the Company’s common stock through the sales agent, if any, will be made by any method that is deemed an “at the market” offering as defined by the U.S. Securities and Exchange Commission. The Company will pay to the sales agent a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock sold through the sales agent under the 2020 At Market Agreement. During the nine months ended September 30, 2024 and 2023, there were no issuances of shares of common stock under the 2020 At Market Agreement. For each of the nine months ended September 30, 2024 and 2023, the Company issued a total of 24,700 and 35,200 shares of common stock, respectively, for dividends on Series A and Series C Preferred Stock.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Fair Value of Financial Instruments, Assets and Liabilities Measured at Fair Value (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	$ 2,159,000	$ 1,004,000
April Note [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	1,202,000	431,000	$ 600,000	$ 249,000
September Note [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	359,000	169,000	238,000	109,000
December Note [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	957,000	404,000	$ 504,000	$ 215,000
Recurring [Member] \| Level 1 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Assets	0	0
Liabilities	0	0
Recurring [Member] \| Level 2 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Assets	0	0
Liabilities	0	0
Recurring [Member] \| April Note [Member] \| Level 3 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	1,202,000	431,000
Recurring [Member] \| September Note [Member] \| Level 3 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	359,000	169,000
Recurring [Member] \| December Note [Member] \| Level 3 [Member]
Assets and Liabilities Measured at Fair Value [Abstract]
Derivative Liability - Contingent Interest	$ 957,000	$ 404,000

Basis of Presentation, Liquidity and Going Concern (Details) - USD ($) $ in Thousands	Nov. 14, 2024	Sep. 30, 2024	Dec. 31, 2023
Basis of Presentation and Liquidity [Abstract]
Cash and cash equivalents		$ 27,060	$ 25,660
Additional Supplemental Line of Credit [Member] \| Richard E. Uihlein [Member] \| Subsequent Event [Member]
Line of Credit, Related Party [Abstract]
Line of credit	$ 6,000

Convertible Notes Payable - Related Party	9 Months Ended
Convertible Notes Payable - Related Party	Sep. 30, 2024
Convertible Notes Payable - Related Party [Member]
Debt Instrument [Line Items]
Convertible Notes Payable - Related Party	3. Convertible Notes Payable – Related Party On April 16, 2021, the Company and Richard E. Uihlein entered into a debt financing arrangement whereby Mr. Uihlein loaned $10,000,000 to the Company. In consideration for the loan, the Company issued a convertible promissory note (the “April 2021 Note”) in the principal amount of ten million dollars. The April 2021 Note has a maturity date of April 16, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company’s common stock at a conversion price equal to $5.00 per share at the option of the noteholder. The April 2021 Note bears interest at the rate of two percent (2%) per annum, compounded annually with an effective interest rate of approximately 3%. For the three months ended September 30, 2024 and 2023, approximately $53,000 and $52,000, respectively, of interest expense was accrued and included with the principal in the financial statements. For the nine months ended September 30, 2024 and 2023, approximately $159,000 and $154,000, respectively, of interest expense was accrued and included with the principal in the financial statements. The April 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the “Additional Interest”) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the April 2021 Note into the Company’s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the April 2021 Note at its inception. The fair value of the contingent interest derivative liability was $420,000 at note inception (April 16, 2021). The fair value of the contingent interest derivative liability was $1,202,000 and $431,000 at September 30, 2024 and December 31, 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability for the three months ended September 30, 2024 and 2023 of $413,000 and $234,000, respectively, was charged to other expense/(income) for the three months ended September 30, 2024 and 2023. The change in the fair value of the derivative liability for the nine months ended September 30, 2024 and 2023 of $771,000 and $(156,000), respectively, was charged to other expense/(income) for the nine months ended September 30, 2024 and 2023. The amortization of the original $420,000 debt discount of $26,000 and $26,000 was recorded as additional interest expense for the three months ended September 30, 2024 and 2023, respectively. The amortization of the original $420,000 debt discount of $78,000 and $78,000 was recorded as additional interest expense for the nine months ended September 30, 2024 and 2023, respectively. On May 14, 2024, Mr. Uihlein, as holder of the April 2021 Note irrevocably elected to convert the entire principal amount of such note, plus accrued and unpaid interest, into shares of common stock of the Company at a price of $5.00 per share, effective as of April 16, 2025, which is the maturity date of the April 2021 Note. The April 2021 Note will remain outstanding and accrue interest until maturity and no shares of common stock will be issued as a result of this election until April 16, 2025. The September 2021 Note has a maturity date of September 17, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company’s common stock at a conversion price equal to $8.64 per share at the option of the noteholder. The September 2021 Note bears interest at the rate of two percent (2%) per annum, compounded annually with an effective interest rate of approximately 3%. For the three months ended September 30, 2024 and 2023, approximately $56,000 and $52,000, respectively, of interest expense was accrued and included with the principal in the financial statements. For the nine months ended September 30, 2024 and 2023, approximately $157,000 and $156,000, respectively, of interest expense was accrued and included with the principal in the financial statements. The September 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the “Additional Interest”) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the September 2021 Note into the Company’s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the September Note at its inception. The fair value of the contingent interest derivative liability was $433,000 at note inception (September 17, 2021). The fair value of the contingent interest derivative liability was $359,000 and $169,000 and September 30, 2024 and December 31, 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability for three months ended September 30, 2024 and 2023 of $50,000 and $78,000, respectively, was recorded to other expense/(income) for three months ended September 30, 2024 and 2023. The change in the fair value of the derivative liability for nine months ended September 30, 2024 and 2023 of $189,000 and $129,000, respectively, was recorded to other expense/(income) for nine months ended September 30, 2024 and 2023. The amortization of the original $433,000 debt discount of $27,000 and $27,000 was recorded as additional interest expense for the three months ended September 30, 2024 and 2023. The amortization of the original $433,000 debt discount of $81,000 and $81,000 was recorded as additional interest expense for the nine months ended September 30, 2024 and 2023. On December 20, 2021, the second of the two promissory notes under the Loan Agreement was executed and delivered, (the “December 2021 Note”) to evidence the second loan in the principal amount of $10,000,000. The December 2021 Note has a maturity date of December 20, 2025, is prepayable at the option of the Company in whole or in part at any time and is convertible into the Company’s common stock at a conversion price equal to $5.43 per share at the option of the noteholder. The December Note bears interest at the rate of two percent (2%) per annum, compounded annually with an effective interest rate of approximately 3%. For three months ended September 30, 2024 and 2023, approximately $52,000 and $51,000, respectively, of interest expense was accrued and included with the principal in the financial statements. For nine months ended September 30, 2024 and 2023, approximately $156,000 and $152,000, respectively, of interest expense was accrued and included with the principal in the financial statements. The December 2021 Note also includes a contingent interest component that requires the Company to pay additional interest at a rate of two and one-half percent (2.5%) per quarter (10% per annum) (the “Additional Interest”) beginning on the date of issuance of this Note and ending on the maturity date, provided however, that such payment is only required if and only if the noteholder elects to convert the entire balance of the December 2021 Note into the Company’s common stock on or prior to maturity. As the contingent event is not based on creditworthiness, such feature is not clearly and closely related to the host instrument and accordingly must be bifurcated and recognized as a derivative liability and a debt discount on the December Note at its inception. The fair value of the contingent interest derivative liability was $415,000 at note inception (December 20, 2021). The fair value of the contingent interest derivative liability was $957,000 and $404,000 at September 30, 2024 and December 31, 2023, respectively, and is recognized as a derivative liability in the consolidated balance sheet. The change in the fair value of the derivative liability for three months ended September 30, 2024 and 2023 of $291,000 and $178,000, respectively was recorded to other expense/(income) for three months ended September 30, 2024 and 2023. The change in the fair value of the derivative liability for nine months ended September 30, 2024 and 2023 of $553,000 and $290,000, respectively was recorded to other expense/(income) for nine months ended September 30, 2024 and 2023. The amortization of the original $415,000 debt discount of $26,000 and $26,000 was recorded as additional interest expense for three months ended September 30, 2024 and 2023, respectively. The amortization of the original $415,000 debt discount of $78,000 and $78,000 was recorded as additional interest expense for nine months ended September 30, 2024 and 2023, respectively. The Company’s contractual cash obligations related to the outstanding convertible notes payable is a repayment of the September 2021 Note of the $10,000,000 plus accrued interest on September 17, 2025 and a repayment of the December 2021 Note of the $10,000,000 plus accrued interest on December 30, 2025, unless converted at the option of the noteholder.

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Galectin Sciences LLC (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended		117 Months Ended	129 Months Ended
Galectin Sciences LLC (Details) - USD ($)	Jan. 31, 2014	Dec. 31, 2014	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2024
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Amount expanded in cash			$ 1,400,000	$ 1,770,000
Galectin Sciences, LLC [Member]
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Initial cash investment	$ 400,000
Equity ownership percentage			85.20%		85.20%	85.20%
Amount expanded in cash		$ 400,000
Contribution for expenses			$ 313,000			$ 4,093,000
Galectin Sciences, LLC [Member] \| SBH [Member]
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Equity ownership percentage	50.00%
Contribution for expenses					$ 711,000
Galectin Sciences, LLC [Member] \| SBH [Member] \| IPR&D [Member]
Investments in and Advances to Affiliates, Schedule of Investments [Abstract]
Estimated fair value of asset contributed to joint venture	$ 400,000

Stock-Based Compensation, Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Weighted Average Assumptions for Stock Options Granted [Abstract]
Risk-free interest rate	3.88%	3.84%
Expected life of the options	5 years 4 months 24 days	5 years 6 months
Expected volatility of the underlying stock	75.00%	86.00%
Expected dividend rate	0.00%	0.00%

Commitments and Contingencies (Details)	9 Months Ended
Commitments and Contingencies (Details)	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Contract cancelation notice period	30 days

Accrued Expenses and Other (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Accrued Expenses and Other [Abstract]
Legal and accounting fees	$ 96,000	$ 40,000
Accrued compensation	1,059,000	1,129,000
Lease liability	$ 32,000	$ 46,000
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total	Total
Accrued research and development costs and other	$ 10,399,000	$ 7,967,000
Total	$ 11,586,000	$ 9,182,000

Common Stock Warrants

9 Months Ended

Sep. 30, 2024

Common Stock Warrants [Abstract]

Common Stock Warrants

6. Common Stock Warrants

The following table summarizes the common stock warrant activity from December 31, 2023 through September 30, 2024:

	Shares			Weighted Average Exercise Price
Outstanding, December 31, 2023		9,256,493		$	4.22
Granted		600,000			3.70
Exercised		(125,093	)		3.00
Forfeited/cancelled		(108,455	)		4.49
Outstanding, September 30, 2024		9,622,945		$	4.20

The weighted average expiration of the warrants outstanding as of September 30, 2024 is 2.2 years.

Fair Value of Financial Instruments, Key Assumptions (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Stock Price [Member] \| April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	2.75	1.66
Stock Price [Member] \| September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	2.75	1.66
Stock Price [Member] \| December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	2.75	1.66
Conversion Price of Conversion Feature [Member] \| April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	5	5
Conversion Price of Conversion Feature [Member] \| September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	8.64	8.64
Conversion Price of Conversion Feature [Member] \| December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	5.43	5.43
Term [Member] \| April Note [Member]
Key Assumptions [Abstract]
Term	6 months 14 days	1 year 3 months 14 days
Term [Member] \| September Note [Member]
Key Assumptions [Abstract]
Term	11 months 15 days	1 year 8 months 19 days
Term [Member] \| December Note [Member]
Key Assumptions [Abstract]
Term	1 year 2 months 19 days	1 year 11 months 19 days
Risk Free Interest Rate [Member] \| April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.0523	0.0479
Risk Free Interest Rate [Member] \| September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.0398	0.0423
Risk Free Interest Rate [Member] \| December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.0398	0.0423
Credit Adjusted Discount Rate [Member] \| April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.1144	0.1286
Credit Adjusted Discount Rate [Member] \| September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.1144	0.1286
Credit Adjusted Discount Rate [Member] \| December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.1144	0.1286
Volatility [Member] \| April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.78	0.69
Volatility [Member] \| September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.68	0.75
Volatility [Member] \| December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0.69	0.72
Dividend Rate [Member] \| April Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0	0
Dividend Rate [Member] \| September Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0	0
Dividend Rate [Member] \| December Note [Member]
Key Assumptions [Abstract]
Derivative liability, measurement input	0	0

Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2024

Fair Value of Financial Instruments [Abstract]

Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis

Level 3 assets and liabilities measured and recorded at fair value on a recurring basis at September 30, 2024 and December 31, 2023 were as follows:

	September 30, 2024		December 31, 2023
Derivative Liability – Contingent Interest April Note	$	1,202,000	$	431,000
Derivative Liability – Contingent Interest September Note	$	359,000	$	169,000
Derivative Liability – Contingent Interest December Note	$	957,000	$	404,000

April Note [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Key Assumptions Used in Model at Inception

The April Note derivative liability – contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at September 30, 2024 and December 31, 2023 are as follows:

	September 30, 2024			December 31, 2023
Stock Price	$	2.75		$	1.66
Conversion Price of conversion feature	$	5.00		$	5.00
Term	0.54 years			1.29 years
Risk Free Interest Rate		5.23	%		4.79	%
Credit Adjusted Discount Rate		11.44	%		12.86	%
Volatility		78	%		69	%
Dividend Rate		0	%		0	%

Roll Forward of Derivative Liability - Contingent Interest

The roll forward of the April Note derivative liability – contingent interest is as follows for the nine months ended September 30, 2024 and 2023:

Balance – December 31, 2023	$	431,000
Fair Value Adjustment		771,000
Balance – September 30, 2024	$	1,202,000

Balance – December 31, 2022	$	249,000
Fair Value Adjustment		351,000
Balance – September 30, 2023	$	600,000

September Note [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Key Assumptions Used in Model at Inception

The September Note derivative liability – contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at September 30, 2024 and December 31, 2023 are as follows:

	September 30, 2024			December 31, 2023
Stock Price	$	2.75		$	1.66
Conversion Price of conversion feature	$	8.64		$	8.64
Term	.96 years			1.72 years
Risk Free Interest Rate		3.98	%		4.23	%
Credit Adjusted Discount Rate		11.44	%		12.86	%
Volatility		68	%		75	%
Dividend Rate		0	%		0	%

Roll Forward of Derivative Liability - Contingent Interest

The roll forward of the September Note derivative liability – contingent interest is as follows:

Balance – December 31, 2023	$	169,000
Fair Value Adjustment		190,000
Balance – September 30, 2024	$	359,000

Balance – December 31, 2022		109,000
Fair Value Adjustment		129,000
Balance – September 30, 2023	$	238,000

December Note [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Key Assumptions Used in Model at Inception

The December Note derivative liability – contingent interest was valued using a Monte Carlo Geometric Brownian Stock Path Model. The key assumptions used in the model at September 30, 2024 and December 31, 2023 are as follows:

	September 30, 2024			December 31, 2023
Stock Price	$	2.75		$	1.66
Conversion Price of conversion feature	$	5.43		$	5.43
Term	1.22 years			1.97 years
Risk Free Interest Rate		3.98	%		4.23	%
Credit Adjusted Discount Rate		11.44	%		12.86	%
Volatility		69	%		72	%
Dividend Rate		0	%		0	%

Roll Forward of Derivative Liability - Contingent Interest

The roll forward of the December Note derivative liability – contingent interest is as follows:

Balance – December 31, 2023	$	404,000
Fair Value Adjustment		553,000
Balance – September 30, 2024	$	957,000

Balance – December 31, 2022	$	215,000
Fair Value Adjustment		289,000
Balance – September 30, 2023	$	504,000

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
Series C super dividend redeemable convertible preferred stock, shares authorized (in shares)	1,000	1,000
Series C super dividend redeemable convertible preferred stock, shares issued (in shares)	176	176
Series C super dividend redeemable convertible preferred stock, shares outstanding (in shares)	176	176
Series C super dividend redeemable convertible preferred stock, redemption value	$ 8,124,000
Series C super dividend redeemable convertible preferred stock liquidation value	$ 1,760,000
Stockholders' equity (deficit):
Undesignated stock, par value (in dollars per share)	$ 0.01	$ 0.01
Undesignated stock, shares authorized (in shares)	20,000,000	20,000,000
Undesignated stock, shares designated (in shares)	20,000,000	20,000,000
Series A 12% convertible preferred stock, shares authorized (in shares)	1,742,500	1,742,500
Series A 12% convertible preferred stock, shares issued (in shares)	1,235,000	1,235,000
Series A 12% convertible preferred stock, shares outstanding (in shares)	1,235,000	1,235,000
Series A 12% convertible preferred stock, liquidation value	$ 1,235,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	62,308,075	61,852,914
Common stock, outstanding (in shares)	62,308,075	61,852,914

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 7,595	$ 7,732	$ 25,462	$ 23,902
General and administrative	1,471	1,434	4,543	4,609
Total operating expenses	9,066	9,166	30,005	28,511
Total operating loss	(9,066)	(9,166)	(30,005)	(28,511)
Other income (expense):
Interest income	93	62	254	156
Interest expense	(1,494)	(835)	(3,815)	(1,945)
Change in fair value of derivative	(753)	(489)	(1,514)	(769)
Total other income (expense)	(2,154)	(1,262)	(5,075)	(2,558)
Net loss	(11,220)	(10,428)	(35,080)	(31,069)
Preferred stock dividends	(18)	6	(90)	(57)
Warrant modification		(3,619)		(3,619)
Net loss applicable to common stockholders	$ (11,238)	$ (14,041)	$ (35,170)	$ (34,745)
Net loss per common share - basic (in dollars per share)	$ (0.18)	$ (0.24)	$ (0.57)	$ (0.58)
Net loss per common share - diluted (in dollars per share)	$ (0.18)	$ (0.24)	$ (0.57)	$ (0.58)
Weighted average common shares outstanding - basic (in shares)	62,278	59,704	62,163	59,590
Weighted average common shares outstanding - diluted (in shares)	62,278	59,704	62,163	59,590

Fair Value of Financial Instruments, Roll Forward of Derivative Liability (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Roll Forward of Derivative Liability [Roll Forward]
Balance	$ 1,004,000
Fair Value Adjustment	1,514,000	$ 769,000
Balance	2,159,000
April Note [Member]
Roll Forward of Derivative Liability [Roll Forward]
Balance	431,000	249,000
Fair Value Adjustment	771,000	351,000
Balance	1,202,000	600,000
September Note [Member]
Roll Forward of Derivative Liability [Roll Forward]
Balance	169,000	109,000
Fair Value Adjustment	190,000	129,000
Balance	359,000	238,000
December Note [Member]
Roll Forward of Derivative Liability [Roll Forward]
Balance	404,000	215,000
Fair Value Adjustment	553,000	289,000
Balance	$ 957,000	$ 504,000

Common Stock Warrants (Details)	9 Months Ended
Common Stock Warrants (Details)	Sep. 30, 2024 $ / shares shares
Weighted Average Exercise Price [Abstract]
Weighted average expiration term of warrants outstanding	2 years 2 months 12 days
Warrants [Member]
Common Stock Warrants shares [Roll Forward]
Outstanding at beginning of period (in shares) \| shares	9,256,493
Granted (in shares) \| shares	600,000
Exercised (in shares) \| shares	(125,093)
Forfeited/cancelled (in shares) \| shares	(108,455)
Outstanding at end of period (in shares) \| shares	9,622,945
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 4.22
Granted (in dollars per share) \| $ / shares	3.7
Exercised (in dollars per share) \| $ / shares	3
Forfeited/cancelled (in dollars per share) \| $ / shares	4.49
Outstanding at end of period (in dollars per share) \| $ / shares	$ 4.2

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2024	Nov. 08, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Document Transition Report	false
Entity File Number	001-31791
Entity Registrant Name	GALECTIN THERAPEUTICS INC.
Entity Central Index Key	0001133416
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	04-3562325
Entity Address, Address Line One	4960 Peachtree Industrial Blvd.
Entity Address, Address Line Two	Suite 240
Entity Address, City or Town	Norcross
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30071
City Area Code	678
Local Phone Number	620 -3186
Title of 12(b) Security	Common Stock
Trading Symbol	GALT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		62,761,825

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2024 shares	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		Securities Trading Plans of Directors and Executive Officers During the fiscal quarter ended September 30 2024, Joel Lewis, Jack Callicutt, and Khurram Jamil, the Company’s CEO, CFO and CMO, respectively, each adopted a Rule 10b5-1 trading plan, as disclosed below. Other than as disclosed, no officers or directors, as defined in Rule 16a-1(f), adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the fiscal quarter ended September 30, 2024. On July 25, 2024, Joel Lewis adopted a Rule 10b5-1 trading plan with a trading plan effective date of December 1, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 185,250 shares of the Company’s common stock until December 31, 2025. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in Company securities. On July 18, 2024, Jack Callicutt adopted a Rule 10b5-1 trading plan with a trading plan effective date of December 1, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 627,456 shares of the Company’s common stock until December 31, 2025. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in Company securities. On August 20, 2024, Khurram Jamil adopted a Rule 10b5-1 trading plan with a trading plan effective date of December 1, 2024, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to an amount of shares needed to cover taxes with respect to the vesting of an RSU grant of 30,000 shares, plus up to 60% of such remaining shares, plus the sale of up to another 25,000 shares pursuant to exercise of stock options. Sales under the plan may occur until December 31, 2025. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in Company securities.
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Sale [Member] \| Joel Lewis [Member]
Trading Arrangements, by Individual
Name	Joel Lewis
Title	CEO
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	July 25, 2024
Arrangement Duration	396 days
Aggregate Available	185,250	185,250
Sale [Member] \| Jack Callicutt [Member]
Trading Arrangements, by Individual
Name	Jack Callicutt
Title	CFO
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	July 18, 2024
Arrangement Duration	396 days
Aggregate Available	627,456	627,456
Sale [Member] \| Khurram Jamil [Member]
Trading Arrangements, by Individual
Name	Khurram Jamil
Title	CMO
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 20, 2024
Arrangement Duration	396 days
Aggregate Available	0	0

Supplemental Convertible Lines of Credit - Related Party	9 Months Ended
	Sep. 30, 2024
Supplemental Convertible Line of Credit - Related Party [Abstract]
Supplemental Convertible Lines of Credit - Related Party	10. Supplemental Convertible Lines of Credit – Related Party On March 29, 2024, the Company and Richard E. Uihlein (the “Lender”) entered into a Supplemental Line of Credit Letter Agreement (the “Supplemental Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $10.0 million (the “Supplemental Line of Credit”) to finance the Company’s working capital needs. The Company may draw upon the Supplemental Line of Credit through March 31, 2025. Each advance made pursuant to the Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a “Promissory Note,” and collectively, the “Promissory Notes”), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before January 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid. At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company’s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share. In connection with the Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 200,000 shares of the Company’s common stock, par value $0.001 per share (collectively, the “Warrants”). The Company shall issue to the Lender Warrants ratably, upon borrowings under the Supplemental Line of Credit, with exercise prices equal to 150% of the closing price of the Company’s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. The Warrants expire on July 31, 2029. On September 30, 2024, the Company executed a $10 million Promissory Note under the Supplemental Line of Credit. The interest rate on this draw is 6.13% (Applicable Federal Rate for short term loans on date of draw of 5.01% plus 2%). The effective interest rate is approximately 6.4%. The principal and accrued interest is convertible at the option of the Lender at $3.00 per share. In accordance with the Credit Agreement, the Company issued the Lender a Warrant to purchase up to 200,000 shares of Company’s Common Stock at an exercise price of $4.13 per share, which Warrant is exercisable upon issuance. The fair value of the 200,000 warrants vested at closing on September 30, 2024, was $307,780 at the date of issuance based on the following assumptions: an expected life of 4.83 years, volatility of 78%, risk free interest rate of 3.58% and zero dividends. The proceeds were allocated between the Promissory Note and the warrants issued, and the amount allocated to the warrants was recorded as a debt discount netted against principal amortized on a straight-line basis, which is not materially different than the effective interest method, from October 1, 2024 through January 31, 2026. On November 14, 2024, the Company and Richard E. Uihlein (the “Lender”) entered into an additional Supplemental Line of Credit Letter Agreement (the “November 2024 Supplemental Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $6.0 million (the “November 2024 Supplemental Line of Credit”) to finance the Company’s working capital needs. The Company may draw upon the November 2024 Supplemental Line of Credit through March 31, 2025. Each advance made pursuant to the November 2024 Supplemental Credit Agreement shall be evidenced by an unsecured, convertible promissory note (individually, a “Promissory Note,” and collectively, the “Promissory Notes”), and bear interest at the Applicable Federal Rate for short term loans, plus two (2%) percent. Principal and interest on the Promissory Notes are due on or before March 31, 2026. Only with the consent of the Lender, may the Promissory Notes be prepaid, in whole or in part, at any time without premium or penalty, but with interest on the amount or amounts prepaid. At the election of Lender, the principal and accrued interest on Promissory Note(s) may be converted into the number of shares of the Company’s Common Stock equal to the amount of principal and accrued interest on such Promissory Note divided by the price equal to the closing price of the Common Stock on the date of such Promissory Note, but in no event less than $3.00 per share. In connection with the November 2024 Supplemental Credit Agreement, the Company agreed to issue the Lender warrants to purchase up to an aggregate of 120,000 shares of the Company’s common stock, par value $0.001 per share (collectively, the “Warrants”). The Company shall issue to the Lender Warrants ratably, upon borrowings under the November 2024 Supplemental Line of Credit, with exercise prices equal to 150% of the closing price of the Company’s common Stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share. The Warrants expire on July 31, 2029.

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2024

Stock-Based Compensation [Abstract]

Components of Stock-Based Compensation Expense

Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
	in thousands
Research and development	$	340	$	223	$	709	$	972
General and administrative		175		363		633		884
Total stock-based compensation expense	$	515	$	586	$	1,342	$	1,856

Stock Option Activity

The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2023 through September 30, 2024:

	Shares			Weighted Average Exercise Price
Outstanding, December 31, 2023		6,333,841		$	2.66
Granted		1,373,000			1.86
Exercised		(49,583	)		(1.22	)
Options forfeited/cancelled		(348,750	)		(6.35	)
Outstanding, September 30, 2024		7,308,508		$	2.35

Weighted Average Assumptions Used to Determine Fair Value of Options Granted

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:

	Nine Months Ended September 30,			Nine Months Ended September 30,
	2024			2023
Risk-free interest rate		3.88	%		3.84	%
Expected life of the options	5.4 years			5.5 years
Expected volatility of the underlying stock		75	%		86	%
Expected dividend rate		0	%		0	%

Basis of Presentation, Liquidity and Going Concern	9 Months Ended
Basis of Presentation, Liquidity and Going Concern	Sep. 30, 2024
Basis of Presentation, Liquidity and Going Concern [Abstract]
Basis of Presentation, Liquidity and Going Concern	1. Basis of Presentation, Liquidity and Going Concern Galectin Therapeutics Inc. and subsidiaries (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions. The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of September 30, 2024 and the results of its operations for the three and nine months ended September 30, 2024 and 2023 and its cash flows for the nine months ended September 30, 2024 and 2023. All adjustments made to the interim financial statements include all those of a normal and recurring nature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2023 are derived from the Company’s audited consolidated financial statements as of that date, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form 10-K for the year ended December 31, 2023. The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At September 30, 2024, the company had $27,060,000 of unrestricted cash and cash equivalents available to fund future operations. In addition, on November 14, 2024, the Company entered into a second supplemental unsecured $6 million line of credit financing with its chairman, Richard E. Uihlein (see note 9). The Company believes there is sufficient cash to fund currently planned operations approximately through May 2025. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements. The ability of the Company to continue as a going concern is likely dependent on the results of its NAVIGATE clinical trial expected in December 2024 and its ability to raise capital; however, the Company’s cash position may not be sufficient to support its daily operations after May 2025. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved. The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011.

Stock-Based Compensation, Restricted Stock Grants and Employment Agreement (Details) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Jan. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Restricted Stock Grants [Abstract]
Amortized expense		$ 515,000	$ 586,000		$ 1,342,000	$ 1,856,000
Vesting percentage of Restricted Stock Units					100.00%
Unrecognized compensation cost		1,154,000			$ 1,154,000
Restricted Stock [Member]
Restricted Stock Grants [Abstract]
Restricted stock awards granted (in shares)	408,000
Amortized expense		163,000			488,000
Restricted stock units valued at grant	$ 734,000
Board Chairman [Member] \| Restricted Stock [Member]
Restricted Stock Grants [Abstract]
Restricted stock awards granted (in shares)	23,256						36,036
Amortized expense	$ 40,000						$ 40,000
Chief Executive Officer [Member]
Restricted Stock Grants [Abstract]
Stock based compensation expense				$ 112,000
Unrecognized compensation cost		$ 0			$ 0
Chief Executive Officer [Member] \| Deferred Bonus [Member]
Restricted Stock Grants [Abstract]
Percentage of base salary paid in cash							20.00%	20.00%
Percentage of base salary paid in deferred stock units							80.00%	80.00%
Percentage of DSUs shall be credited on March 1, 2023								25.00%
Percentage of DSUs shall be credited on March 1, 2024		50.00%	25.00%		50.00%	25.00%		50.00%
Percentage of DSUs shall be credited on September 1, 2028								25.00%
Percentage of DSUs shall be credited on March 1, 2025							50.00%
Percentage of DSUs shall be credited on January 5, 2026							50.00%
Stock based compensation expense								$ 210,000
Common stock reserved for future issuance (in shares)				72,440				143,836
Common Stock Weighted average Grant Date fair Value (in dollars per share)				$ 1.55				$ 1.46
Shares unissued (in shares)		367,800	183,900		367,800	183,900
Shares withheld to cover income tax withholding (in shares)					153,288	75,529
Income tax payment withholding					$ 300,445	$ 156,345
Shares issued (in shares)					214,512	108,371
Reclassification of accrued compensation to additional paid in capital					$ 210,000

Stock-Based Compensation, Components of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	$ 515	$ 586	$ 1,342	$ 1,856
Research and Development [Member]
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	340	223	709	972
General and Administrative [Member]
Stock-Based Compensation Expense [Abstract]
Total stock-based compensation expense	$ 175	$ 363	$ 633	$ 884

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 27,060	$ 25,660
Prepaid expenses and other current assets	1,606	2,050
Total current assets	28,666	27,710
Other assets	306	490
Total assets	28,972	28,200
Current liabilities:
Accounts payable	2,795	6,431
Accrued expenses and other	11,586	9,182
Current portion of convertible notes payable and accrued interest, net of discounts - related party (Note 3)	10,518	0
Derivative liabilities (Note 4)	359	0
Accrued dividends payable	0	63
Total current liabilities	25,258	15,676
Convertible notes payable and accrued interest, net of discounts - related party (Note 3)	21,094	30,902
Derivative liabilities (Note 4)	2,159	1,004
Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Notes 9 and 10)	72,942	40,839
Other liabilities	0	20
Total liabilities	121,453	88,441
Commitments and contingencies (Note 11)
Series C super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at September 30, 2024 and December 31, 2023, redemption value: $8,124,000, liquidation value: $1,760,000 at September 30, 2024	1,723	1,723
Stockholders' equity (deficit):
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at September 30, 2024 and December 31, 2023 respectively	0	0
Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,235,000 issued and outstanding at September 30, 2024 and December 31, 2023, liquidation value $1,235,000 at September 30, 2024	500	500
Common stock, $0.001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023, 62,308,075 and 61,852,914 issued and outstanding at September 30, 2024 and December 31, 2023, respectively	62	61
Additional paid-in capital	294,776	291,847
Retained deficit	(389,542)	(354,372)
Total stockholders' equity (deficit)	(94,204)	(61,964)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$ 28,972	$ 28,200

Leases (Details)	9 Months Ended
Leases (Details)	Sep. 30, 2024 USD ($) Lease	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Lease Commitments [Abstract]
Number of operating leases \| Lease	1
Term of contract	38 months
Free rent period	6 months 15 days
Security deposit	$ 6,000
Right to use lease asset	$ 26,000
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets
Current lease liability	$ 32,000		$ 46,000
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued Liabilities, Current		Accrued Liabilities, Current
Maturity of Operating Lease [Abstract]
2024	$ 13,000
2025	20,000
Total	33,000
Less imputed interest	1,000
Present value of lease liability	$ 32,000
Discount rate on present value of lease payments	11.00%
General and Administrative Expense [Member]
Lease Commitments [Abstract]
Lease cost	$ 39,000	$ 39,000

Loss Per Share (Details) - shares	9 Months Ended
Loss Per Share (Details) - shares	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	49,402,846	33,232,640
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	9,622,945	9,700,961
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	7,308,508	6,426,758
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	401,256	0
Convertible Note Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	6,872,504	6,267,886
Line of Credit [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	24,698,459	10,333,695
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]
Amount excluded from calculation (in shares)	499,174	503,340

Loss Per Share

9 Months Ended

Sep. 30, 2024

Loss Per Share [Abstract]

Loss Per Share

7. Loss Per Share

Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares and other potential common shares then outstanding. Potential common shares consist of common shares issuable upon the assumed exercise of in-the-money stock options and warrants and potential common shares related to the conversion of the preferred stock. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share.

Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:

	September 30, 2024		September 30, 2023
	(shares)		(shares)
Warrants to purchase shares of common stock		9,622,945		9,700,961
Options to purchase shares of common stock		7,308,508		6,426,758
Restricted stock units		401,256		—
Shares of common stock issuable upon conversion of convertible notes payable – related party		6,872,504		6,267,886
Shares of common stock issuable upon conversion of convertible line of credit – related party		24,698,459		10,333,695
Shares of common stock issuable upon conversion of preferred stock		499,174		503,340
		49,402,846		33,232,640

Leases (Tables)

9 Months Ended

Sep. 30, 2024

Leases [Abstract]

Maturity of Operating Lease

Maturity of operating lease as of September 30, 2024 in thousands:

2024		13
2025		20
Total		33
Less imputed interest		1
Present value of lease liability	$	32

Common Stock (Details) - USD ($) $ in Millions	9 Months Ended
Common Stock (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Common Stock [Abstract]
Issuance of common stock (in shares)	62,308,075		61,852,914
2020 Market Agreement [Member]
Common Stock [Abstract]
Aggregate offering price	$ 40.0
Percentage of commission rate to be paid to sales agent	3.00%
Issuance of common stock (in shares)	0	0
2020 Market Agreement [Member] \| Series A and Series C Preferred Stock [Member]
Common Stock [Abstract]
Common stock issued for dividends (in shares)	24,700	35,200

Convertible Line of Credit - Related Party (Details) - USD ($)						3 Months Ended				6 Months Ended	9 Months Ended		12 Months Ended
	Jun. 28, 2024	Mar. 29, 2024	Dec. 29, 2023	Dec. 19, 2022	Jul. 25, 2022	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Convertible Line of Credit - Related Party [Abstract]
Proceeds from lines of credit											$ 30,000,000	$ 20,000,000
Common stock, par value (in dollars per share)						$ 0.001				$ 0.001	$ 0.001		$ 0.001
Expected life											5 years 4 months 24 days	5 years 6 months
Expected volatility											75.00%	86.00%
Risk free interest rate											3.88%	3.84%
Expected dividend											0.00%	0.00%
Warrants [Member]
Convertible Line of Credit - Related Party [Abstract]
Warrants issuance value					$ 738,000
Expected life										4 years 9 months 29 days	7 years
Expected volatility										78.00%	92.00%
Risk free interest rate										3.58%	3.19%
Expected dividend										0.00%	0.00%
Amortization of interest expense						$ 52,000	$ 52,000				$ 156,000	$ 157,000
Warrant One [Member]
Convertible Line of Credit - Related Party [Abstract]
Warrants issuance value				$ 160,780
Expected life											7 years
Expected volatility											91.00%
Risk free interest rate											4.06%
Expected dividend											0.00%
Amortization of interest expense											$ 39,000	39,000
Warrant Two [Member]
Convertible Line of Credit - Related Party [Abstract]
Warrants issuance value	$ 260,000	$ 277,389						$ 179,920	$ 296,680				$ 193,745
Expected life	5 years 10 days	5 years 3 months 29 days						6 years 29 days	6 years 3 months 29 days				5 years 8 months 12 days
Expected volatility	77.00%	75.00%						85.00%	88.00%				79.00%
Risk free interest rate	4.29%	4.19%						3.59%	3.94%				4.49%
Expected dividend	0.00%	0.00%						0.00%	0.00%				0.00%
Amortization of interest expense											78,000	52,000
Warrant Three [Member]
Convertible Line of Credit - Related Party [Abstract]
Amortization of interest expense											52,000	18,000
Warrant Four [Member]
Convertible Line of Credit - Related Party [Abstract]
Amortization of interest expense											70,000
Warrant Five [Member]
Convertible Line of Credit - Related Party [Abstract]
Amortization of interest expense											76,000
Warrant Six [Member]
Convertible Line of Credit - Related Party [Abstract]
Amortization of interest expense											$ 41,000
Richard E. Uihlein [Member]
Convertible Line of Credit - Related Party [Abstract]
Common stock, par value (in dollars per share)					$ 0.001
Percentage of warrants equal to the closing price of common stock					150.00%
Warrants expiry date						Jul. 31, 2029				Jul. 31, 2029	Jul. 31, 2029
Richard E. Uihlein [Member] \| Warrants [Member]
Convertible Line of Credit - Related Party [Abstract]
Exercise price of warrant (in dollars per share)					$ 5
Richard E. Uihlein [Member] \| Warrant One [Member]
Convertible Line of Credit - Related Party [Abstract]
Exercise price of warrant (in dollars per share)	$ 3.39	$ 3.59	$ 3	$ 3				$ 3	$ 3.26
Richard E. Uihlein [Member] \| Line of Credit [Member]
Convertible Line of Credit - Related Party [Abstract]
Line of credit					$ 60,000,000
Additional short term borrowing interest rate	2.00%	2.00%	2.00%		2.00%
Borrowings repayment due date					Jan. 31, 2026
Share price (in dollars per share)	$ 3	$ 3	$ 3
Proceeds from lines of credit	$ 10,000,000	$ 10,000,000	$ 10,000,000
Interest rate on short term loans	7.01%	6.62%	7.13%
Short term borrowing interest rate	5.01%	4.62%	5.13%
Short term borrowing effective interest rate	7.40%	7.10%	7.50%
Richard E. Uihlein [Member] \| Line of Credit [Member] \| December 2022 Promissory Note [Member]
Convertible Line of Credit - Related Party [Abstract]
Additional short term borrowing interest rate				2.00%
Share price (in dollars per share)						$ 3				$ 3	$ 3
Proceeds from lines of credit				$ 10,000,000
Interest rate on short term loans				6.46%
Short term borrowing interest rate				4.46%
Short term borrowing effective interest rate				7.10%
Accrued interest						$ 1,217,000	517,000			$ 1,217,000	$ 1,217,000	517,000
Richard E. Uihlein [Member] \| Line of Credit [Member] \| March 2023 Promissory Note [Member]
Convertible Line of Credit - Related Party [Abstract]
Additional short term borrowing interest rate									2.00%
Share price (in dollars per share)									$ 3
Proceeds from lines of credit									$ 10,000,000
Interest rate on short term loans									6.41%
Short term borrowing interest rate									4.41%
Short term borrowing effective interest rate									7.10%
Accrued interest						1,006,000	325,000			1,006,000	1,006,000	325,000
Richard E. Uihlein [Member] \| Line of Credit [Member] \| June 2023 Promissory Note [Member]
Convertible Line of Credit - Related Party [Abstract]
Additional short term borrowing interest rate								2.00%
Share price (in dollars per share)								$ 3
Proceeds from lines of credit								$ 10,000,000
Interest rate on short term loans								6.34%
Short term borrowing interest rate								4.34%
Short term borrowing effective interest rate								7.10%
Accrued interest						822,000	$ 159,000			822,000	822,000	$ 159,000
Richard E. Uihlein [Member] \| Line of Credit [Member] \| December 2023 Promissory Note [Member]
Convertible Line of Credit - Related Party [Abstract]
Accrued interest						548,000				548,000	548,000
Richard E. Uihlein [Member] \| Line of Credit [Member] \| March 2024 Promissory Note [Member]
Convertible Line of Credit - Related Party [Abstract]
Accrued interest						$ 166,000				$ 166,000	$ 166,000
Richard E. Uihlein [Member] \| Line of Credit [Member] \| Minimum [Member]
Convertible Line of Credit - Related Party [Abstract]
Share price (in dollars per share)					$ 3
Richard E. Uihlein [Member] \| Line of Credit [Member] \| Maximum [Member]
Convertible Line of Credit - Related Party [Abstract]
Share price (in dollars per share)					$ 10
Common Stock [Member] \| Richard E. Uihlein [Member]
Convertible Line of Credit - Related Party [Abstract]
Warrants to purchase common stock (in shares)					1,700,000
Common stock, par value (in dollars per share)						$ 0.001				$ 0.001	$ 0.001
Common Stock [Member] \| Richard E. Uihlein [Member] \| Maximum [Member]
Convertible Line of Credit - Related Party [Abstract]
Warrants to purchase common stock (in shares)	200,000	200,000	200,000	200,000	500,000	200,000		200,000	200,000	200,000	200,000
Warrants to purchase additional common stock (in shares)					1,200,000

Accrued Expenses and Other

9 Months Ended

Sep. 30, 2024

Accrued Expenses and Other [Abstract]

Accrued Expenses and Other

2. Accrued Expenses and Other

Accrued expenses consist of the following:

	September 30, 2024		December 31, 2023
	(in thousands)
Legal and accounting fees	$	96	$	40
Accrued compensation		1,059		1,129
Lease liability		32		46
Accrued research and development costs and other		10,399		7,967
Total	$	11,586	$	9,182

Research and development expenses, including personnel costs, allocated facility costs, lab supplies, outside services, contract laboratory costs related to manufacturing drug product, clinical trials and preclinical studies are charged to research and development expense as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expense when the service has been performed or when the goods have been received. Our current NAVIGATE clinical trial is being supported by third-party contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed by CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses and related expenses associated with the conduct of clinical trials, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients have been enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We base our estimates on the best information available at the time. We monitor patient enrollment levels and related activities to the extent possible through discussions with CRO personnel and based our estimates of clinical trial costs on the best information available at the time. However, additional information may become available to us which will allow us to make a more accurate estimate in future periods. In that event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.

Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2024

Loss Per Share [Abstract]

Antidilutive Securities Excluded from Computation of Earnings Per Share

	September 30, 2024		September 30, 2023
	(shares)		(shares)
Warrants to purchase shares of common stock		9,622,945		9,700,961
Options to purchase shares of common stock		7,308,508		6,426,758
Restricted stock units		401,256		—
Shares of common stock issuable upon conversion of convertible notes payable – related party		6,872,504		6,267,886
Shares of common stock issuable upon conversion of convertible line of credit – related party		24,698,459		10,333,695
Shares of common stock issuable upon conversion of preferred stock		499,174		503,340
		49,402,846		33,232,640

Galectin Sciences LLC	9 Months Ended
Galectin Sciences LLC	Sep. 30, 2024
Galectin Sciences LLC [Abstract]
Galectin Sciences LLC	13. Galectin Sciences LLC In January 2014, we created Galectin Sciences, LLC (the “LLC” or “Investee”), a collaborative joint venture co-owned by SBH Sciences, Inc. (“SBH”), to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The LLC was initially capitalized with a $400,000 cash investment to fund future research and development activities, which was provided by the Company, and specific in-process research and development (“IPR&D”) contributed by SBH. The estimated fair value of the IPR&D contributed by SBH, on the date of contribution, was $400,000. Initially, the Company and SBH each had a 50% equity ownership interest in the LLC, with neither party having control over the LLC. Accordingly, from inception through the fourth quarter of 2014, the Company accounted for its investment in the LLC using the equity method of accounting. Under the equity method of accounting, the Company’s investment was initially recorded at cost with subsequent adjustments to the carrying value to recognize additional investments in or distributions from the Investee, as well as the Company’s share of the Investee’s earnings, losses and/or changes in capital. The estimated fair value of the IPR&D contributed to the LLC was immediately expensed upon contribution as there was no alternative future use available at the point of contribution. The operating agreement provides that if either party does not desire to contribute its equal share of funding required after the initial capitalization, then the other party, providing all of the funding, will have its ownership share increased in proportion to the total amount contributed from inception. In the fourth quarter of 2014, after the LLC had expended the $400,000 in cash, SBH decided not to contribute its share of the funding required. Cumulatively, the Company has contributed a total of $4,093,000, including $313,000 for the nine months ended September 30, 2024, for expenses of the LLC. Since the end of 2014, SBH has contributed $711,000 for expenses in the LLC. As of September 30, 2024, the Company’s ownership percentage in the LLC was 85.2%. The Company accounts for the interest in the LLC as a consolidated, less than wholly owned subsidiary. Because the LLC’s equity is immaterial, the value of the non-controlling interest is also deemed to be immaterial.

Convertible Notes Payable - Related Party (Details)						3 Months Ended		9 Months Ended
Convertible Notes Payable - Related Party (Details)	Dec. 30, 2025 USD ($)	Sep. 17, 2025 USD ($)	May 14, 2024 $ / shares shares	Dec. 20, 2021 USD ($) PromissoryNote $ / shares	Apr. 16, 2021 USD ($)	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Sep. 17, 2021 USD ($)
Convertible Notes Payable - Related Party [Abstract]
Fair value of derivative liability						$ 2,159,000		$ 2,159,000		$ 1,004,000
Change in fair value of derivative						(753,000)	$ (489,000)	(1,514,000)	$ (769,000)
April 2021 Note [Member]
Convertible Notes Payable - Related Party [Abstract]
Change in fair value of derivative						413,000	234,000	771,000	(156,000)
Amortization of debt discount						420,000		420,000
Additional interest expense						$ 26,000	26,000	$ 78,000	78,000
April 2021 Note [Member] \| Richard E. Uihlein [Member]
Convertible Notes Payable - Related Party [Abstract]
Debt financing arrangement					$ 10,000,000
Convertible note principal					$ 10,000,000
Maturity date			Apr. 16, 2025					Apr. 16, 2025
Conversion price (in dollars per share) \| $ / shares			$ 5			$ 5		$ 5
Common stock, shares issued (in shares) \| shares			0
Interest rate compounded annually						2.00%		2.00%
Effective interest rate						3.00%		3.00%
Accrued interest expense						$ 53,000	52,000	$ 159,000	154,000
Additional interest rate per quarter					2.50%
Additional interest rate per annum from issuance date to maturity date period					10.00%
Fair value of derivative liability					$ 420,000	1,202,000		1,202,000		431,000
September 2021 Note [Member]
Convertible Notes Payable - Related Party [Abstract]
Change in fair value of derivative						50,000	78,000	189,000	129,000
Amortization of debt discount						433,000		433,000
Additional interest expense						$ 27,000	27,000	$ 81,000	81,000
September 2021 Note [Member] \| Forecast [Member]
Convertible Notes Payable - Related Party [Abstract]
Convertible note payable repayment		$ 10,000,000
September 2021 Note [Member] \| Richard E. Uihlein [Member]
Convertible Notes Payable - Related Party [Abstract]
Maturity date								Sep. 17, 2025
Conversion price (in dollars per share) \| $ / shares						$ 8.64		$ 8.64
Interest rate compounded annually						2.00%		2.00%
Effective interest rate						3.00%		3.00%
Accrued interest expense						$ 56,000	52,000	$ 157,000	156,000
Additional interest rate per quarter											2.50%
Additional interest rate per annum from issuance date to maturity date period											10.00%
Fair value of derivative liability						359,000		$ 359,000		169,000	$ 433,000
December 2021 Note [Member]
Convertible Notes Payable - Related Party [Abstract]
Convertible note principal				$ 10,000,000
Maturity date								Dec. 20, 2025
Number of promissory notes evidenced by loans agreement \| PromissoryNote				2
Conversion price (in dollars per share) \| $ / shares				$ 5.43
Interest rate compounded annually				2.00%
Effective interest rate				3.00%
Accrued interest expense						52,000	51,000	$ 156,000	152,000
Additional interest rate per quarter				2.50%
Additional interest rate per annum from issuance date to maturity date period				10.00%
Fair value of derivative liability				$ 415,000		957,000		957,000		$ 404,000
Change in fair value of derivative						291,000	178,000	553,000	290,000
Amortization of debt discount						415,000		415,000
Additional interest expense						$ 26,000	$ 26,000	$ 78,000	$ 78,000
December 2021 Note [Member] \| Forecast [Member]
Convertible Notes Payable - Related Party [Abstract]
Convertible note payable repayment	$ 10,000,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (35,080)	$ (31,069)
Adjustments to reconcile net loss to net cash flows from operating activities:
Stock-based compensation expense	1,857	1,764
Amortization of right to use lease asset	27	24
Non-cash interest expense	748	505
Change in fair value of derivative liabilities	1,514	769
Changes in operating assets and liabilities:
Prepaid expenses and other assets	444	711
Accounts payable, accrued expenses and other liabilities	(1,553)	(2,406)
Accrued interest on convertible debt - related party	3,067	1,439
Net cash from operating activities	(28,976)	(28,263)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from convertible line of credit - related party	30,000	20,000
Net proceeds from exercise of common stock warrants	376	10,033
Net cash flows from financing activities	30,376	30,033
NET DECREASE IN CASH AND CASH EQUIVALENTS	1,400	1,770
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	25,660	18,592
CASH AND CASH EQUIVALENTS, END OF PERIOD	27,060	20,362
NONCASH FINANCING ACTIVITIES:
Payment of preferred stock dividends in common stock	90	57
Reclassification of accrued bonus to additional paid in capital	0	210
Common stock purchase warrants issued in connection with related party line of credit	$ 845	477
Warrant Modification		$ 3,619

Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2024

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

4. Fair Value of Financial Instruments

The Company has certain financial assets and liabilities recorded at fair value. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts reflected in the consolidated balance sheets for cash equivalents, accounts payable and accrued expenses approximate their carrying value due to their short-term nature. There were no level 1 or 2 assets or liabilities at September 30, 2024 or December 31, 2023. See below for Fair Value of Derivatives related to Convertible Notes Payable at September 30, 2024 and December 31, 2023, which are level 3 liabilities.

Level 3 assets and liabilities measured and recorded at fair value on a recurring basis at September 30, 2024 and December 31, 2023 were as follows:

	September 30, 2024		December 31, 2023
Derivative Liability – Contingent Interest April Note	$	1,202,000	$	431,000
Derivative Liability – Contingent Interest September Note	$	359,000	$	169,000
Derivative Liability – Contingent Interest December Note	$	957,000	$	404,000

	September 30, 2024			December 31, 2023
Stock Price	$	2.75		$	1.66
Conversion Price of conversion feature	$	5.00		$	5.00
Term	0.54 years			1.29 years
Risk Free Interest Rate		5.23	%		4.79	%
Credit Adjusted Discount Rate		11.44	%		12.86	%
Volatility		78	%		69	%
Dividend Rate		0	%		0	%

The roll forward of the April Note derivative liability – contingent interest is as follows for the nine months ended September 30, 2024 and 2023:

Balance – December 31, 2023	$	431,000
Fair Value Adjustment		771,000
Balance – September 30, 2024	$	1,202,000

Balance – December 31, 2022	$	249,000
Fair Value Adjustment		351,000
Balance – September 30, 2023	$	600,000

	September 30, 2024			December 31, 2023
Stock Price	$	2.75		$	1.66
Conversion Price of conversion feature	$	8.64		$	8.64
Term	.96 years			1.72 years
Risk Free Interest Rate		3.98	%		4.23	%
Credit Adjusted Discount Rate		11.44	%		12.86	%
Volatility		68	%		75	%
Dividend Rate		0	%		0	%

The roll forward of the September Note derivative liability – contingent interest is as follows:

Balance – December 31, 2023	$	169,000
Fair Value Adjustment		190,000
Balance – September 30, 2024	$	359,000

Balance – December 31, 2022		109,000
Fair Value Adjustment		129,000
Balance – September 30, 2023	$	238,000

	September 30, 2024			December 31, 2023
Stock Price	$	2.75		$	1.66
Conversion Price of conversion feature	$	5.43		$	5.43
Term	1.22 years			1.97 years
Risk Free Interest Rate		3.98	%		4.23	%
Credit Adjusted Discount Rate		11.44	%		12.86	%
Volatility		69	%		72	%
Dividend Rate		0	%		0	%

The roll forward of the December Note derivative liability – contingent interest is as follows:

Balance – December 31, 2023	$	404,000
Fair Value Adjustment		553,000
Balance – September 30, 2024	$	957,000

Balance – December 31, 2022	$	215,000
Fair Value Adjustment		289,000
Balance – September 30, 2023	$	504,000

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Other Legal Proceedings The Company records accruals for such contingencies to the extent that the Company concludes that their occurrence is probable, and the related damages are estimable. There are no significant pending legal proceedings. Clinical Trial and Research Commitments The Company has entered into agreements with contractors for research and development activities to further its product candidates. The contracts generally may be canceled at any time by providing thirty days’ notice.

Stock-Based Compensation

9 Months Ended

Sep. 30, 2024

Stock-Based Compensation [Abstract]

Stock-Based Compensation

5. Stock-Based Compensation

Following is the stock-based compensation expense related to common stock options, restricted common stock, common stock warrants and deferred stock units:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
	in thousands
Research and development	$	340	$	223	$	709	$	972
General and administrative		175		363		633		884
Total stock-based compensation expense	$	515	$	586	$	1,342	$	1,856

The following table summarizes the stock option activity in the Company’s equity incentive plans, including non-plan grants to Company executives, from December 31, 2023 through September 30, 2024:

	Shares			Weighted Average Exercise Price
Outstanding, December 31, 2023		6,333,841		$	2.66
Granted		1,373,000			1.86
Exercised		(49,583	)		(1.22	)
Options forfeited/cancelled		(348,750	)		(6.35	)
Outstanding, September 30, 2024		7,308,508		$	2.35

As of September 30, 2024, there was $1,154,000 of unrecognized compensation related to 2,475,171 unvested options, which is expected to be recognized over a weighted–average period of approximately 1 year. The weighted-average grant date fair value for options granted during the nine months ended September 30, 2024 was $1.23. The Company granted 1,373,000 stock options during the nine months ended September 30, 2024.

The fair value of all other options granted is determined using the Black-Scholes option-pricing model. The following weighted average assumptions were used:

	Nine Months Ended September 30,			Nine Months Ended September 30,
	2024			2023
Risk-free interest rate		3.88	%		3.84	%
Expected life of the options	5.4 years			5.5 years
Expected volatility of the underlying stock		75	%		86	%
Expected dividend rate		0	%		0	%

In January 2024, the Company’s board chairman elected to take restricted stock grants in lieu of cash retainers for 2024. A total of 23,256 shares of restricted stock valued at approximately $40,000 is being amortized to expense on a straight-line basis until December 31, 2024 when the stock vests in full. In January 2023, the Company’s board chairman elected to take restricted stock grants in lieu of cash retainers for 2023. A total of 36,036 shares of restricted stock valued at approximately $40,000 was being amortized to expense on a straight-line basis until December 31, 2023 when the stock vested in full.

In January 2024, the Company issued 408,000 restricted stock units to its employees valued at $734,000 at the date of grant. These restricted stock units will vest 100% if the Company publicly presents the results of the Interim Analysis of its NAVIGATE clinical trial on or before December 31, 2024. The Company believes that is probable that the vesting condition will be met and is amortizing the restricted stock unit expense ratably in 2024. The amount of expense recorded during the three and nine months ended September 30, 2024 was $163,000 and $488,000 respectively.

In September 2020, the Company entered into an employment agreement with its new Chief Executive Officer whereby 20% of his base salary and performance bonuses will be paid in cash, and 80% will be paid in the form of deferred stock units (“DSUs”) through December 31, 2022 in accordance with the terms and subject to the provisions set forth in the DSU Agreement. DSUs credited to Mr. Lewis as of any date shall be fully vested and nonforfeitable at all times. Pursuant to an amendment to the DSU Agreement in July 2022, the Company shall issue the shares earned through December 31, 2022 underlying the outstanding whole number of DSUs credited to Mr. Lewis as follows: twenty five percent shall be issued on March 1, 2023, fifty percent shall be issued on March 1, 2024 and twenty five percent shall be issued on September 1, 2028. Additionally, a 2023 DSU Agreement was executed in July 2022, whereby Mr. Lewis would continue to receive 20% of salary in cash and 80% in DSUs through December 31, 2023. The shares under the 2023 DSU Agreement are to be issued fifty percent on March 1, 2025 and fifty percent on January 5, 2026.

For the three months ended March 31, 2023, approximately $112,000 of his compensation was recorded as stock compensation expense representing 72,440 shares of common stock to be issued under the DSU agreement with a weighted average grant date fair value of $1.55 per share.

On March 1, 2024, fifty percent of the DSU’s were issued to Mr. Lewis in accordance with the DSU Agreement. A total of 367,800 shares were due to be issued; however, 153,288 shares were withheld to cover income tax withholding of $300,445 resulting in 214,512 shares actually issued. On March 1, 2023, twenty five percent of the DSU’s were issued to Mr. Lewis in accordance with the DSU Agreement. A total of 183,900 shares were due to be issued; however, 75,529 shares were withheld to cover income tax withholding of $156,345 resulting in 108,371 shares actually issued.

Also, Mr. Lewis’ bonus for the year ended December 31, 2022 of $210,000 (which was included in accrued compensation at December 31, 2022) was approved in January 2023 and represents 143,836 shares of common stock to be issued under the DSU agreement with a grant date fair value of $1.46 per share. The $210,000 was reclassified from accrued compensation to additional paid in capital in January 2023.

There is no unrecognized compensation expense related to the DSUs.